Skip to main content
. 2017 Dec 29;7:522. doi: 10.7916/D8Z61VW5

Table 1. Clinical and Demographic Characteristics of ET Patients and RBD Subgroups.

All ET Patients (n=53) ET-RBD (n=14) ET-nonRBD (n=39) p value (ET-RBD vs. ET-nonRBD)
Age, yrs 73.6 (±11.0) 70.1 (±15.5) 74.8 (±8.6) 0.558
Female sex 29 (54.7%) 8 (57.1%) 21 (53.8%) 0.832
Age at onset, yrs 53.7 (±20.3) 51.8 (±22.6) 54.4 (±19.8) 0.693
Onset before 65 yrs 31 (58.5%) 8 (57.1%) 23 (58.9%) 0.905
Disease duration, yrs 19.9 (±17.3) 18.3 (±15.8) 20.5 (±18.0) 0.746
Family history 30 (56.6%) 7 (50.0%) 23 (58.9%) 0.496
Onset of tremor
Localization
 Upper limbs 48 (90.6%) 13 (93%) 35 (89.7%) 1.0001
 Other2 5 (9.4%) 1 (7.1%) 4 (10.2%)
Symmetry3
 Symmetrical onset 36 (72%) 12 (92.3%) 24 (64.9%) 0.0781
 Asymmetrical onset 14 (28%) 1 (7.7%) 13 (35.1%)
On treatment 41 (77.4%) 12 (85.7%) 29 (74.4%) 0.384
 Propanolol 15 (36.5%) 6 (50.0%) 9 (31.0%)
 Primidone 22 (53.6%) 6 (50.0%) 16 (55.1%)
 Topiramate 6 (14.6%) 6 (20.7%)
 Others4 4 (9.7%)
RBDSQ scores (mean±SD) 3.7 (±2.9) 8.0 (±2.0) 2.2 (±1.2) <0.001
SCOPA-AUT (mean± SD)
 SCOPA-total 9.3 (±7.0) 13.9 (±9.6) 7.7 (±5.1) 0.017*
 Gastrointestinal 2.4 (±2.5) 3.9 (±3.5) 1.8 (±1.8) 0.067
 Urinary 3.9 (±3.4) 4.8 (±4.4) 3.6 (±2.9) 0.758
 Cardiovascular 1.2 (±1.9) 1.8 (±2-5) 0.9 (±1.7) 0.157
 Thermoregulatory 1.3 (±1.8) 2.5 (±2.0) 0.9 (±1.6) 0.001***
 Pupillomotor 0.6 (±1.0) 0.0 (±1.3) 0.4 (±0.9) 0.137
Comorbidities 26 8 18 0.480
 Hypertension 20 8 12 0.081
 Diabetes 9 1 8 0.4161
 BPH 3 0 3 0.5571

Abbreviations: BPH, Benign Prostatic Hyperplasia; ET, Essential Tremor; RBD, Rapid Eye Movement Sleep Behavior Disorder; RBDSQ, Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire; SCOPA-AUT, Scales for Outcomes in Parkinson’s Disease-Autonomic; SD, Standard Deviation.

1

Fisher’s exact t test.

2

Head (n=3), both lower limbs (n=2).

3

For total ET patients n=50, for ET+RBD n=13, for ET no RBD n=37.

4

Gabapentine (n=2), alprazolam (n=1), trihexyphenidyl (n=1).

*

p<0.05;

***

p<0.005